56 results on '"Hartung, H.P."'
Search Results
2. P23 Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany – CONFIDENCE Baseline Characteristics
3. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions
4. 20. Practical application of subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy – results from a multicenter, randomized, double-blind, placebo-controlled trial (The PATH Study)
5. Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
6. FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis
7. P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis
8. P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
9. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS
10. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the Path study
11. P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies
12. P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFNβ-1a–controlled OPERA I and OPERA II studies
13. Effect of fingolimod versus interferon-beta1a on neda-4 (no evidence of disease activity or worsening) in the transforms study
14. Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study
15. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis
16. Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study
17. Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study
18. TLR 3 ligand poly I:C does not induce encephalitogenic T cells nor essentially alter cytokine production in SJL EAE
19. Fingolimod-Compassionate-use-Programm
20. Re-expression of N-cadherin in remyelinating lesions of experimental inflammatory demyelination
21. A Case of Relapsing-Remitting Neuroborreliosis? Challenges in the Differential Diagnosis of Recurrent Myelitis
22. Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab
23. Erratum zu: Messung von Publikationsleistungen
24. INTRAVENOUS IMMUNOGLOBULIN IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: A DOSE-FINDING TRIAL
25. Messung von Publikationsleistungen
26. FTY720– eine neue orale, einmal täglich anzuwendende therapeutische Option für Multiple Sklerose: Update aus dem internationalen Studienprogramm
27. Active immunization with amyloid-beta 1–42 induces severe memory impairment in healthy mice
28. Expert opinion: Guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies
29. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
30. MRI correlates of lesion pathology in T-cell clone mediated mouse experimental autoimmune encephalomyelitis
31. Inzidenz und biologische Aktivität von neutralisierenden Antikörpern gegen Interferon-beta
32. B cell responses in HIV infection of the central nervous system
33. Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation
34. Zuverlässige Bestimmung neutralisierender Antikörper gegen Interferon-beta durch Capture ELISA und in vivo MxA Test
35. Mitoxantron hemmt die Migrationsfähigkeit immunkompetenter Zellen
36. Der Beitrag der Phänotypisierung von Liquorzellen mittels Flusszytometrie zur Diagnostik neurologischer Erkrankungen
37. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis
38. Analyse der erworbenen Immunantwort in Blut und Liquor von Patienten mit HIV Infektion
39. Anti-CD20 Therapie mit Rituximab zur Behandlung der fulminant schubförmig verlaufenden Multiplen Sklerose
40. Fatigue bei Multipler Sklerose - Erfassung klinischer, neuropsychologischer und immunologischer Parameter unter immunmodulatorischer Therapie mit Glatiramerazetat
41. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis
42. A randomized, double-blind, dose-comparison study of weekly interferon -1a in relapsing MS
43. Statins as immunomodulators: Comparison with interferon- 1b in MS
44. Leserbrief
45. Prevalence of Multiple Sclerosis in Austria
46. Nervenwachstumsfaktor (NGF) in der Behandlung der diabetischen Polyneuropathie
47. Experimental autoimmune myositis in the Lewis rat: lack of spontaneous T-cell apoptosis and therapeutic response to glucocorticosteroid application
48. Hereditäre motorisch-sensible Neuropathien (Charcot-Marie-Tooth Syndrom) und verwandte Neuropathien
49. L-2-Hydroxyglutaric aciduria: Normal L-2-hydroxyglutarate dehydrogenase activity in liver from two new patients
50. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.